KAINOS LaboratoriesTSE:4556 39 Altman Z-Score is 4.69 as of Jul. 11, 2026, which is 55% above its 10-year median of 3.03. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 808 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 63.99% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 4.69 is strong.
KAINOS Laboratories has a Altman Z-Score of 4.69, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for KAINOS Laboratories's Altman Z-Score or its related term are showing as below:
TSE:4556'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.37 Med: 3.03 Max: 4.69
Current: 4.69
During the past 13 years, KAINOS Laboratories's highest Altman Z-Score was 4.69. The lowest was 2.37. And the median was 3.03.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
KAINOS Laboratories Altman Z-Score Related Terms
KAINOS Laboratories Altman Z-Score Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: Altman Z-Score Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
KAINOS Laboratories's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.475
+
1.4
*
0.5415
+
3.3
*
0.0669
+
0.6
*
4.282
+
1.0
*
0.5728
=
4.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
KAINOS Laboratories (TSE:4556) has a Altman Z-Score of 4.69 as of Jul. 11, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on KAINOS Laboratories and its competitors. This is 55% above median its historical median of 3.03. Over the past decade, KAINOS Laboratories' Altman Z-Score has ranged from 2.37 to 4.69. According to the industry distribution chart, KAINOS Laboratories ranks #291 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 36%.
Is KAINOS Laboratories' Altman Z-Score too high?
KAINOS Laboratories' current Altman Z-Score of 4.69 is 55% above median its 10-year median of 3.03. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 4.69. The Medical Devices & Instruments industry median Altman Z-Score is 3.01. KAINOS Laboratories' value of 4.69 is 56.1% above this industry median. Based on the distribution chart, KAINOS Laboratories ranks #291 out of 808 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Altman Z-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #291 out of 808 companies for Altman Z-Score. This puts KAINOS Laboratories in the upper half of its industry. The industry median Altman Z-Score is 3.01. KAINOS Laboratories' value of 4.69 is 56.1% above this benchmark. Historically, KAINOS Laboratories' own Altman Z-Score has ranged from 2.37 to 4.69 over the past decade. While the company's 10-year median is 3.03 vs. the industry median of 3.01, KAINOS Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.01, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current Altman Z-Score of 4.69 is 56.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current Altman Z-Score is 4.69, which is 55% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current Altman Z-Score is 4.69, which is 55% above median its 10-year median of 3.03 and 56.1% above the Medical Devices & Instruments industry median of 3.01. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Altman Z-Score is 4.69 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
Altman Z-Score: 4.69 (55% above median its 10-year median of 3.03)
GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
Industry Position: 56.1% above the Medical Devices & Instruments median (#291 of 808)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score
Get the complete analysis for TSE:4556
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
